The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCL
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, briefly discusses recent updates from the Phase I/II BRUIN study (NCT03740529), which is evaluating the safety and efficacy of pirtobrutinib in patients with mantle cell lymphoma (MCL). Dr Cohen comments on the poor prognosis associated with patients who relapse or progress on Bruton’s tyrosine kinase (BTK) inhibitors, and then goes on to highlight the role of pirtobrutinib as a promising option for these patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
